GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Metagenomi Inc (NAS:MGX) » Definitions » Price-to-Funds-From-Operations

MGX (Metagenomi) Price-to-Funds-From-Operations : (As of Apr. 29, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Metagenomi Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Metagenomi Business Description

Industry
Traded in Other Exchanges
N/A
Address
5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.